|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-9-6
|
|
pubmed:abstractText |
The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1531-8249
|
|
pubmed:author |
pubmed-author:AndersenAllanA,
pubmed-author:BastinChristineC,
pubmed-author:BormansGuyG,
pubmed-author:BrooksDavid JDJ,
pubmed-author:BuckleyChrisC,
pubmed-author:FarrarGillG,
pubmed-author:GarrauxGaëtanG,
pubmed-author:HasselbalchSteenS,
pubmed-author:IvanoiuAdrianA,
pubmed-author:KornerAlexA,
pubmed-author:LinK ZKZ,
pubmed-author:MinthonLennartL,
pubmed-author:NelissenNatalieN,
pubmed-author:OweniusRikardR,
pubmed-author:SalmonEricE,
pubmed-author:ThurfjellLennartL,
pubmed-author:TriauEricE,
pubmed-author:Van LaereKoenK,
pubmed-author:VandenbergheRikR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
319-29
|
|
pubmed:meshHeading |
pubmed-meshheading:20687209-Aged,
pubmed-meshheading:20687209-Alzheimer Disease,
pubmed-meshheading:20687209-Benzothiazoles,
pubmed-meshheading:20687209-Brain,
pubmed-meshheading:20687209-Cognition Disorders,
pubmed-meshheading:20687209-Diagnostic Imaging,
pubmed-meshheading:20687209-Fluorodeoxyglucose F18,
pubmed-meshheading:20687209-Humans,
pubmed-meshheading:20687209-Middle Aged,
pubmed-meshheading:20687209-Positron-Emission Tomography,
pubmed-meshheading:20687209-Radiopharmaceuticals,
pubmed-meshheading:20687209-Sensitivity and Specificity
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
|
|
pubmed:affiliation |
Laboratory for Cognitive Neurology, Catholic University Leuven, Leuven, Belgium. rik.vandenberghe@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
